Healio21h
Few hospitalized adults with type 2 diabetes prescribed SGLT2, GLP-1 medication
Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...
Medscape5d
Age Affects Efficacy of Popular Diabetes Drugs
A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...
HealthDay on MSN4d
Age Differences Seen in Efficacy of Type 2 Diabetes Treatments
SGLT2 inhibitors more cardioprotective in older versus younger people despite smaller reduction in HbA1c with older age ...
‘First of its kind’ medication can significantly reduce heart attacks and strokes
A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...
Science Daily17h
A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
Medpage Today on MSN4d
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Medical Xpress5d
Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes
SGLT2 inhibitors may have kidney- and heart-protective effects in adults with type 1 diabetes Nov 8, 2021 Sotagliflozin shows benefit for difficult-to-treat form of heart failure ...
News Medical on MSN4d
Sotagliflozin could be used to reduce the risk of deadly cardiovascular events, trial shows
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
MedPage Today5d
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
"The stroke benefit observed in the present study appears to be unique to sotagliflozin, as it has not been observed in trials of selective SGLT2 inhibitors." "These results demonstrate a new ...
Medical News Today4d
Can drugs like Ozempic help with COPD?
Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people ...